T-Therapeutics
- Company typePrivate
- Founded2023
- HeadquartersCambridge, United Kingdom
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
T-Therapeutics firmographics
Firmographics- Name
- T-Therapeutics
- Legal name
- T-Therapeutics Limited
- Website
- https://t-therapeutics.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
T-Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
- akta.pro industry
- CAR-T & TCR-T TherapiesBispecific & Multispecific AntibodiesHealthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Keywords
Where T-Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United Kingdom
- HQ region
- Europe
Offices2 records
Markets served
T-Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D
Marketing channels3 records
T-Therapeutics product offering
Product offeringCore offering
T-Therapeutics is a preclinical-stage biopharmaceutical company developing a pipeline of first-in-class TCR-CD3 bispecific drug candidates for the treatment of solid tumors and autoimmune diseases. The company leverages its proprietary OpTiMus transgenic mouse platform to generate high-specificity, fully human T cell receptors (TCRs) against previously undruggable intracellular targets, and pairs them with next-generation proprietary CD3 T cell engagers in its modular T-Bridge format to create bispecific therapeutics.
Product overview
T-Therapeutics is a next-generation T cell engager company developing a portfolio of first-in-class TCR-CD3 bispecifics for cancer and autoimmune diseases. The company's core technology stack consists of the OpTiMus® transgenic mouse platform for generating high-quality human TCRs, and the T-Bridge® modular format for optimal presentation of TCR-CD3 complexes. These platforms are combined to create bispecific therapeutics that engage T cells to target cancer cells or pathogenic immune cells with high specificity and potency.
Differentiator
Problem solved
Functional benefit
Products and services
- OpTiMus® Platform
Companies that use T-Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
T-Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability1 record
Feature4 records
T-Therapeutics partnerships and signals
Strategic signalScale indicators3 records
Recent moves8 records
Expansion highlights5 records
T-Therapeutics competitors and assessment
Company assessmentDirect peers
- Immunocore: Closely comparable UK-based biotech developing TCR-based therapeutics, including TCR-CD3 bispecifics (ImmTAC platform). Tebentafusp is the first FDA-approved TCR therapeutic. Direct competitor for TCR discovery platforms and TCR-CD3 bispecific pipelines in oncology.
- Adaptimmune Therapeutics: Clinical-stage biotech developing TCR-based cell therapies for solid tumours. Directly comparable as a TCR-focused company pursuing solid tumour targets, with overlapping scientific talent pool and a similar target-class approach via engineered TCRs.
- Immatics: Biotech developing TCR-based immunotherapies, including TCR-engineered cell therapies and TCR-bispecifics (TCER). Competes with T-Therapeutics in the TCR therapeutic space, particularly for solid tumour targets and intracellular tumour-associated antigens.
- Harpoon Therapeutics (Merck): Developed T cell engagers (TriTAC platform) for oncology, including trispecific TCEs with extended half-life. Acquired by Merck in 2024. Direct comparable for T cell engager format, dosing-schedule optimisation, and solid tumour TCE design.
- Maverick Therapeutics (Takeda): Developed TCR-bispecifics (COBRA platform) for solid tumours; acquired by Takeda. Closely comparable in terms of TCR-CD3 bispecific approach and target-class focus, providing a reference point for potential strategic exits in the TCR-TCE space.
- Crescendo Biologics: UK-based biotech developing T cell engagers based on a proprietary VH domain platform. Comparable as a TCE-focused UK biotech; notably, T-Therapeutics' CEO Theodora Harold was previously CEO of Crescendo, evidencing shared DNA in TCE strategy.
Emerging players
- Cullinan Oncology: Clinical-stage oncology biotech with bispecific TCE programmes. Comparable as a similarly staged, multi-asset oncology biotech pursuing T cell engager strategies, useful for benchmarking pipeline breadth and capital efficiency.
- F-star Therapeutics: Developed bispecific antibodies using a modular Fc platform, with T cell engagers in oncology. Comparable as a bispecific-focused biotech with modular format technology and shared talent pool (T-Therapeutics' VP of CMC previously held senior CMC roles at F-star).
- Revitope Oncology: Early-stage biotech developing next-generation T cell engagers with tumour-selective activity. Comparable as a small, similarly staged TCE biotech focused on improving the safety/efficacy profile of CD3-engaging bispecifics.
Broad incumbents
- Kymab (Sanofi): Antibody discovery biotech co-founded by T-Therapeutics founder Prof. Allan Bradley, acquired by Sanofi for $1.45B in 2021. Provides reference value for both the underlying transgenic mouse platform lineage and the strategic exit pattern Sanofi has previously pursued with T-Therapeutics founder-built companies.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
T-Therapeutics social profiles
Digital presenceT-Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
T-Therapeutics leadership team
Management profileNumber of profiles
Profiles16 records
T-Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
T-Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about T-Therapeutics
What does T-Therapeutics do?
T-Therapeutics is a preclinical-stage biopharmaceutical company developing a pipeline of first-in-class TCR-CD3 bispecific drug candidates for the treatment of solid tumors and autoimmune diseases. The company leverages its proprietary OpTiMus transgenic mouse platform to generate high-specificity, fully human T cell receptors (TCRs) against previously undruggable intracellular targets, and pairs them with next-generation proprietary CD3 T cell engagers in its modular T-Bridge format to create bispecific therapeutics.
Is T-Therapeutics a public or private company?
T-Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.
When was T-Therapeutics founded?
T-Therapeutics was founded in 2023. It employs 51 to 100 people.
Where is T-Therapeutics based?
T-Therapeutics is headquartered in Cambridge, United Kingdom, in the Europe region.
Who are T-Therapeutics's main competitors?
Direct peers on record are Immunocore, Adaptimmune Therapeutics, Immatics, Harpoon Therapeutics (Merck), Maverick Therapeutics (Takeda) and Crescendo Biologics. Emerging players are Cullinan Oncology, F-star Therapeutics and Revitope Oncology. Kymab (Sanofi) is listed as a broad incumbent.
Does T-Therapeutics have an API?
No public API is recorded for T-Therapeutics.
What industry is T-Therapeutics in?
T-Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAC, CAR-T & TCR-T Therapies, with a secondary code of HLAAAAAF, Bispecific & Multispecific Antibodies. Its NAICS code is 541714 and its SIC code is 2836.